Summary
We evaluated the stability of the aqueous formulation of mesna during storage in syringes and after dilution in beverages and syrups. Measurements of the concentrations of mesna showed that the undiluted formulation was stable for at least 9 days in standard polypropylene syringes at 5°, 24°, and 35°C. There was no detectable oxidation of mesna to dimesna over the course of at least 1 week when mesna was diluted 1:2 and 1:5 in syrups and incubated at 24°C in capped tubes. Concentration changes were clinically negligible for 1:2, 1:10, and 1:100 dilutions of mesna in six carbonated drinks, two juices, and milk after incubation for 24 h at 5°C. Thus, the aqueous mesna formulation is stable when diluted and stored in a variety of beverages and syrups under conditions suitable for oral administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Araujo CE, Tessler J (1983) Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (mesna) to patients with inoperable lung cancer. Eur J Cancer Clin Oncol 19: 195–201
Brock N, Hilgard P, Pohl J, Ormstad K, Orrenius S (1984) Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols. J Cancer Res Clin Oncol 108: 87–97
Burkert H, Lucker PW, Wetzelsberger N, Breuel HP (1984) Bioavailability of orally administered mesna. Arzneimittelforschung 34: 1597–1600
Goren MP, Pratt CB, Meyer WM, Wright RK, Dodge RK, Viar MJ (1989) Mesna excretion and ifosfamide nephrotoxicity in children. Cancer Res 49: 7153–7157
James CA, Mant TG, Rogers HJ (1987) Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. Br J Clin Pharmacol 23: 561–568
Jones MS, Murrell RD, Shaw IC (1985) Excretion of sodium 2-mercaptoethanesulphonate mesna in the urine of volunteers after oral dosing. Eur J Cancer Clin Oncol 21: 553–555
Ormstad K, Orrenius S, Lastbom T, Uehara N, Pohl J, Stekar J, Brock N (1983) Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat. Cancer Res 43: 333–338
Radford JA, Margison JM, Swindell R, Lind MJ, Wilkinson PM, Thatcher N (1990) The stability of ifosfamide in aqueous solution and its suitability for continous 7-day infusion by ambulatory pump. Cancer Chemother Pharmacol 26: 144–146
Riddles PW, Blakely RL, Zerner B (1983) Reassessment of Ellman's reagent. Methods Enzymol 91: 49–60
Rowland CG, Bradford E, Adams P, Haines-Nutt RF, Jakobson K (1984) Infusion of ifosfamide plus mesna. Lancet II: 468
Shaw IC (1987) Mesna — a short review. Cancer Treat Rev 14: 67–86
Shaw IC, Weeks MS (1987) Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing. Eur J Cancer Clin Oncol 23: 933–935
Thannhauser TW, Konishi Y, Scherage HA (1984) Sensitive quantitative analysis of disulfide bonds in polypeptides and proteins. Anal Biochem 138: 181–188
Author information
Authors and Affiliations
Additional information
Supported in part by Bristol-Myers Oncology Division, by grants CA 49529, CA 23099, and CA 21765 from the National Cancer Institute, and by the American Lebanese Syrian Associated Charities
Rights and permissions
About this article
Cite this article
Goren, M.P., Lyman, B.A. & Li, J.T. The stability of mesna in beverages and syrup for oral administration. Cancer Chemother. Pharmacol. 28, 298–301 (1991). https://doi.org/10.1007/BF00685538
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685538